Search results
Results from the WOW.Com Content Network
The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it ...
The approval was updated in September 2021, to include people aged twelve and older. [14] The Moderna Spikevax COVID-19 vaccine was authorized in Canada in September 2021, for people aged 12 and older. [22] [4] [182] The Moderna Spikevax COVID-19 vaccine was authorized in the US in January 2022, for people aged 18 and older. [1] [38] [41]
Moderna is also expecting to get approval to expand the label to high-risk people under the age of 60. It sees the expansion of the product to younger adults as having a $10 billion total ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. [35] [36] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster. [37]
CRISPR's shares are down by 27% year to date, and Moderna's are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why. 1.
Moderna held its annual R&D day this week. Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand ...